Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DOPA PET/CT for Focal Pancreatic Lesions in CHI
NCT01468454Phase 2Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Jan 2009
- Primary completion
- Jun 2014
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluorodopa F 18 in congenital hyperinsulinism (HI), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism at 1 week. Started Jan 2009; status: completed.
02
Drugs
Fluorodopa F 18
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT01468454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468454.